BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.4%

Neg 0% Neu 87.4% Pos 0%

BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.

Comments

No comments yet. Be the first!